EP 1711177 A1 20061018 - 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS
Title (en)
1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS
Title (de)
1H-THIENO 2,3-C-PYRAZOL-DERIVATE ALS KINASE-I-HEMMER
Title (fr)
DERIVES DE 1H-THIENO 2,3-C¨PYRAZOLE UTILISES EN TANT QU'INHIBITEURS DE KINASES
Publication
Application
Priority
- EP 2005001021 W 20050202
- US 54145204 P 20040203
Abstract (en)
[origin: WO2005074922A1] Thieno[2,3-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comrising them are disclosed; the compounds of the invention may be useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
IPC 8 full level
A61K 31/4162 (2006.01); A61P 9/10 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C07D 495/04 (2006.01)
CPC (source: EP KR US)
A61K 31/4162 (2013.01 - EP KR US); A61K 45/06 (2013.01 - KR); A61P 1/04 (2017.12 - EP); A61P 5/14 (2017.12 - EP); A61P 7/00 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 13/08 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 31/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 495/04 (2013.01 - EP KR US); A61K 2300/00 (2013.01 - KR)
Citation (search report)
See references of WO 2005074922A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2005074922 A1 20050818; AP 2006003701 A0 20060831; AR 047531 A1 20060125; AT E396724 T1 20080615; AU 2005210114 A1 20050818; AU 2005210114 B2 20110714; BR PI0507375 A 20070710; CA 2555262 A1 20050818; CA 2555262 C 20141014; CN 1946395 A 20070411; CN 1946395 B 20140402; CR 8546 A 20070530; CY 1108246 T1 20140212; DE 602005007181 D1 20080710; DK 1711177 T3 20080929; DO P2005000014 A 20060815; EA 011032 B1 20081230; EA 200601418 A1 20061229; EC SP066767 A 20061124; EP 1711177 A1 20061018; EP 1711177 B1 20080528; ES 2307144 T3 20081116; GE P20094633 B 20090310; GT 200500020 A 20050906; HK 1101343 A1 20071018; IL 177141 A0 20061210; JP 2007520513 A 20070726; JP 4908233 B2 20120404; KR 20060124734 A 20061205; MA 28429 B1 20070201; MX PA06008787 A 20070119; NO 20063768 L 20061102; NZ 548896 A 20100528; PA 8622801 A1 20051125; PE 20051095 A1 20051231; PL 1711177 T3 20081128; PT 1711177 E 20080904; SI 1711177 T1 20081031; TN SN06244 A1 20071203; TW 200526204 A 20050816; UA 86223 C2 20090410; US 2005187209 A1 20050825; US 2012165311 A1 20120628; US 8138217 B2 20120320; US 8481584 B2 20130709; UY 28738 A1 20050930; ZA 200606179 B 20080227
DOCDB simple family (application)
EP 2005001021 W 20050202; AP 2006003701 A 20050202; AR P050100399 A 20050202; AT 05701307 T 20050202; AU 2005210114 A 20050202; BR PI0507375 A 20050202; CA 2555262 A 20050202; CN 200580005922 A 20050202; CR 8546 A 20060803; CY 081100834 T 20080807; DE 602005007181 T 20050202; DK 05701307 T 20050202; DO 2005000014 A 20050202; EA 200601418 A 20050202; EC SP066767 A 20060810; EP 05701307 A 20050202; ES 05701307 T 20050202; GE AP2005009600 A 20050202; GT 200500020 A 20050203; HK 07106106 A 20070607; IL 17714106 A 20060727; JP 2006551790 A 20050202; KR 20067017754 A 20060901; MA 29227 A 20060803; MX PA06008787 A 20050202; NO 20063768 A 20060823; NZ 54889605 A 20050202; PA 8622801 A 20050203; PE 2005000121 A 20050202; PL 05701307 T 20050202; PT 05701307 T 20050202; SI 200530297 T 20050202; TN SN06244 A 20060803; TW 94102761 A 20050128; UA A200609515 A 20050202; US 201213404697 A 20120224; US 5036005 A 20050203; UY 28738 A 20050203; ZA 200606179 A 20060726